Educational research & price index · Independent Janoshik & MZ Biolabs COA verification

← Verified COAs & $/mg for this compound

Guide|30 CitationsRecovery & HealingFemale-friendly

TB-500 (Thymosin Beta-4) Research Dosing Reference

Also known as: Thymosin Beta-4, Tβ4, Systemic Healing Peptide

Dose Range
1–2.5 mgResearch range
0Typical research window: 1–2.5 mg3 mg

Studied in systemic tissue repair — typically dosed at 1–2.5 mg twice per week (2–5 mg/week total) rather than daily.

Protocol at a Glance
How Often
2× weekly

Twice weekly SubQ (e.g. Mon/Thu) for 2–5 mg/week total

A Typical Run
6–12 weeks

6-week loading phase followed by optional monthly maintenance or 4-week washout.

How It's Taken
Vial

SubQ injection (systemic distribution)

Evidence
Emerging

Preclinical dermal, corneal & cardiac repair trials

Half-Life & 72-Hour Clearance Shape
Not established in humans

Not established in humans for TB-500; no published human pharmacokinetic data

0h18h36h54h72h
On Your SyringeU-100 Insulin Syringe

A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.

5 mg vial · 2 mL water · 0.5 mL syringe
Concentration: 2.5 mg in every mL (25 mcg per unit)
0u10u20u30u40u50u
Low end: 1 mg40 units
High end: 2.5 mg100 units

All U-100: 100 units = 1 mL. 5 doses in the vial at the low end (2 doses at the high end).

Track the doses you run

Save TB-500 (Thymosin Beta-4) to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.

Verified Peptide Vial Suppliers · Sorted by Real $/mg•Checked Nov 11, 2026

TB-500 (Thymosin Beta-4) supplier & $/mg comparison.

Source:
Max $/mg:
Sort:
SwissChems
Independent test results linked on store
US Domestic Vial
Verified Partner Link
$42.36$63.98
10mg Lyophilized Vial
$4.24/mg$6.40/mg retail
Ascension Peptides50% OFF AUTO-APPLIED
Batch COAs (Kovera Labs, MZ Biolabs) on product page
US Domestic Vial
50% Off First Order Link
$27.00 net$54.00
5mg Lyophilized Vial
$5.40/mg$10.80/mg retail
Pure Peptides
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026); code PEPTIDE9544 takes 10% off at checkout
$30.00
5mg vial
$6.00/mg
Bulletproof BioLabs
ILS Laboratories HPLC COA COA-2026-5ZRE0B, lot BPB-2610-001
US Domestic Vial
Vendor-supplied list price (Nov 7, 2026; store requires login)
$60.00
10mg vial
$6.00/mg
Elite Research USA
Batch COA on product page
US Domestic Vial
List price
$65.00
10mg vial
$6.50/mg
Polaris Peptides
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026)
$70.00
10mg vial
$7.00/mg
Ameano Peptides
Batch COA portal on store site
US Domestic Vial
List price (verified Oct 30)
$75.00
10mg vial
$7.50/mg
Protide Health
Per-lot COA (Freedom Diagnostics, HPLC-MS) on product page
US Domestic Vial
List price
$85.00
10mg vial
$8.50/mg
Swift Peptides
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026)
$43.99
5mg vial
$8.80/mg
Direct Peptides
COA per store product page
US Domestic Vial
List price (last verified Nov 4, 2026; store now requires sign-in)
$99.00
10mg vial
$9.90/mg
Peptyes
Horizon Analytical UPLC-MS COA, lot DPS-1698961 (99.46%); COA names Privilege Bio Labs (Peptyes says: its manufacturer)
US Domestic Vial
List price (verified Nov 11, 2026); code PEPTIDEPROTOCOLS takes 10% off at checkout
$102.00
10mg vial
$10.20/mg
Biotech Peptides
COA per store product page
US Domestic Vial
List price (verified Oct 31)
$124.00
10mg vial
$12.40/mg
Core Peptides
COA per store product page
US Domestic Vial
List price (verified Oct 31)
$140.00
10mg vial
$14.00/mg
Limitless Peptides
COA per store product page
US Domestic Vial
Code: PEPTIDEPROTOCOLS
$165.00
10mg vial
$16.50/mg
BioLongevity Labs
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026)
$164.97
10mg vial
$16.50/mg
Sorted strictly by calculated $/mg or 2026 COA score. Only research peptide vial suppliers are included in $/mg benchmarks.
Full Verified $/mg Index →

At a Glance · 2026 FDA / 503A / WADA / Evidence Profile

2026 FDA 503A Cat-2 UpdateTier 3 — Translational Animal & Clinical Obs
Pharmacological Class
Synthetic 7-AA Actin-Sequestering Fragment (Ac-LKKTETQ) of Thymosin Beta-4
Administration Route
Under-the-skin injection (Subcutaneous)
2026 FDA & 503A Status
Not FDA-approved. In April 2026, the FDA removed 14 peptides (including BPC-157, Thymosin Beta-4/TB-500, CJC-1295, Ipamorelin, AOD-9604, Semax, Selank, and DSIP) from the Category 2 503A Interim Bulks List pending formal July 2026 PCAC rulemaking. Available as COA-verified research reference standards or via specialized physician telehealth guidance.
WADA Sport Status
Strictly Prohibited at All Times — WADA Section S2.2 (Peptide Hormones, Growth Factors, GH Fragments, BPC-157 & Thymosin-β4)
Evidence Tier
Tier 3 — Translational Animal & Clinical Obs: Replicated mammalian preclinical models plus extensive off-label physician & community protocol tracking
What is a Peptide?

A short chain of amino acids (2-50) linked by peptide bonds. Smaller than proteins. Your body produces thousands of peptides naturally as signaling molecules that regulate everything from appetite to healing. Therapeutic peptides mimic or enhance these natural signals.

Bottom Line Up Front

TB-500 (Thymosin Beta-4) is a naturally occurring peptide involved in wound healing and tissue repair. It promotes angiogenesis and cell migration. Most evidence is from animal studies and cell culture.

Best evidence for

Wound healing, tissue repair, recovery from injury

Weakest evidence for

Muscle growth, performance enhancement

Pharma equivalent

None

Studies on file

30 (26 human)

EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. TB-500 (Thymosin Beta-4) is not FDA approved for human use (unless specified above). This information does not constitute medical advice.

Overview

TB-500 is the synthetic version of Thymosin Beta-4, a naturally occurring peptide present in virtually all human and animal cells. Research has focused on its role in actin regulation and tissue regeneration.

Mechanisms of Action

  • Regulates actin polymerization
  • Promotes cell migration
  • Modulates inflammatory responses
  • Supports stem cell differentiation

Research Protocols

Summaries of published research. For educational purposes only.

Protocol NameSourceDoseFrequencyDurationRouteEvidenceLinkSave
Wound Healing Study
reported protocol
6 mgWeekly6 weeksSubcutaneousanimal
Baseline & Mid-Cycle Biomarker Bloodwork Panel

Systemic Inflammation, Tissue Repair & Immune Biomarker Panel (TB-500 (Thymosin Beta-4))

Objective inflammatory, hematologic, and trace-mineral markers to quantify connective-tissue recovery, cytokine resolution, and organ safety.

Draw fasted morning labs at Baseline (Day 0) and Mid-Cycle (Week 6–8)

hs-CRP (High-Sensitivity C-Reactive Protein)

Day 0 + Wk 6–8

Why track at baseline: Quantifies baseline systemic IL-6/NF-κB inflammatory burden from tendon, joint, gut, or vascular injury.

Week 6–8 check: Target <1.0 mg/L (optimal <0.5 mg/L) by Week 6–8 as tissue inflammation resolves.

ESR (Sedimentation Rate) & Ferritin

Day 0 + Wk 6–8

Why track at baseline: Tracks chronic connective-tissue and autoimmune/mucosal inflammatory activity alongside iron stores.

Week 6–8 check: Downward trend in ESR confirming structural resolution rather than temporary analgesic masking.

CBC with Differential (WBC, Neutrophil/Lymphocyte Ratio)

Day 0 + Wk 6–8

Why track at baseline: Evaluates innate/adaptive immune balance (especially for Thymosin Alpha-1, Thymosin Beta-4, LL-37 & KPV).

Week 6–8 check: Balanced lymphocyte count and improved Neutrophil-to-Lymphocyte Ratio (NLR 1.2–2.0).

CMP (Liver/Kidney) + Serum Copper & Zinc Ratio

Day 0 + Wk 6–8

Why track at baseline: Verifies baseline hepatic/renal function and checks Copper:Zinc balance before GHK-Cu / GLOW / KLOW protocols.

Week 6–8 check: Maintain 1:1 to 1.2:1 Zinc-to-Copper equilibrium and normal transaminases/creatinine.

Test before and during your protocol: one baseline panel of 100+ Quest biomarkers covering the markers above, plus a mid-cycle retest. No doctor visit required.Code SPAMBASSADOR
Get baseline bloodwork at Superpower

Related Studies

26 Human4 Animal

Finally, translational opportunities are appraised with attention to pharmacokinetics, peptide stability and delivery strategies. Key challenges moving forward include validating efficacy in additional clinically relevant models, overcoming peptide instability and completing comprehensive safety assessments.

Limitations: No placebo control reported. Review article — no new primary data.

2026|Peptides
PubMed

In summary, glutamine effectively ameliorated inflammation and the occurrence of apoptosis by downregulating the pro-inflammatory and pro-fibrotic corneal epithelial cells subclusters and the related I&#x3ba;B&#x3b1;/NF-&#x3ba;B signaling. The present study suggests that glutamine metabolism plays a critical, previously unrecognized role in DED and proposes an attractive strategy to enhance glutamine metabolism by inhibiting the enzyme GLS1 and thus alleviating inflammation-driven DED progression.

Limitations: No placebo control reported.

2025|Signal transduction and targeted therapy
PubMed

The beneficial effects of T&#x3b2;4 were also revealed in 5xfAD model mice. Thus, this study has identified T&#x3b2;4 as a neuroprotective factor that may mitigate altered neurogenesis and AD pathology, highlighting a potential for disease intervention.

Limitations: No placebo control reported.

2025|Stem cell reports
PubMed

pDC depletion during house mite dust challenge enhanced CCR2-dependent inflammatory monocyte-derived cell accumulation, leading to exacerbated TH2-mediated allergic asthma phenotypes. RNA-sequencing analysis revealed that the anti-inflammatory peptide thymosin &#x3b2;4 (T&#x3b2;4) was among the most upregulated genes in asthmatic lung pDCs.

Limitations: No placebo control reported.

2025|The Journal of allergy and clinical immunology
PubMed

Plasma CCN5 levels were significantly reduced and correlated closely with the degree of restenosis in ISR patients. CCN5 expression was significantly decreased in VSMCs of stent-implanted porcine coronary segments and injured mouse femoral arteries, especially in synthetic VSMCs.

Limitations: No placebo control reported.

2025|European heart journal
PubMed

This process mitigates oxidative stress, reduces apoptosis, and promotes revascularization, thereby improving the quality and volume retention of fat grafts. Our findings provide a novel mechanistic insight into the enhancement of fat graft survival and suggest that mitochondrial transplantation and T&#x3b2;4 are potential therapeutic strategies to improve clinical outcomes in autologous fat transfer procedures.

Limitations: No placebo control reported.

2025|Free radical biology &amp; medicine
PubMed

Furthermore, MN@EVsT&#x3b2;4 patches showed significant efficacy in reversing senescence and promoting wound healing in diabetic wound models. Thus, the engineered ADSC-EVs, combined with separable microneedle patches, represent a promising bioengineering strategy for clinical wound management.

Limitations: No placebo control reported.

2025|Advanced science (Weinheim, Baden-Wurttemberg, Germany)
PubMed

The simultaneous analytical method for TB-500 and its metabolites was developed and validated. The study found that Ac-LK was the primary metabolite with the highest concentration in rats at 0-6 h intervals.

Limitations: No placebo control reported.

2024|Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
PubMed

Moreover, as our initial results imply, it is not the differentiated, yet most likely the local epidermal progenitor cells which are the primary targets of the molecule. Our present results unveil a new, thus far undiscovered field regarding clinical utilization for TB4 in the future.

Limitations: No placebo control reported.

2024|International immunopharmacology
PubMed

Endothelial Sirt1 deficiency, by inhibiting autophagy and activating nuclear factor-kappa B signaling, augments expression and secretion of thymosin beta-4 (T&#x3b2;4) that promotes insulin signaling in skeletal myotubes. Thus, unlike in skeletal myocytes, Sirt1 deficiency in the endothelium promotes glucose homeostasis by stimulating skeletal muscle insulin sensitivity through a blood-borne mechanism, and augmented secretion of T&#x3b2;4 by Sirt1-deficient endothelial cells boosts insulin signaling in skeletal muscle cells.

Limitations: Animal study only — human translation uncertain.

2023|Nature communications
PubMed

Moreover, we discovered TB4 is capable of epicardial progenitor activation, and revealed the effect is independent of hypoxic injury. By observing the above results, we believe, further discoveries and consequential postnatal administration of developmentally relevant candidate molecules such as TB4 may likely result in reversing aging processes and accelerate organ regeneration in the human body.

Limitations: No placebo control reported. Review article — no new primary data.

2023|International immunopharmacology
PubMed

It prevented LPS-induced amyloid burden in APP/PS1 mice but increased astrocytic and microglial proliferation in the hippocampus of LPS-treated WT mice. These data show that T&#x3b2;4 can alleviate the adverse effects of systemic LPS in the brain by preventing exacerbation of amyloid deposition in AD mice and by inducing reactive microgliosis in aging WT mice.

Limitations: Animal study only — human translation uncertain.

2023|International immunopharmacology
PubMed

Adjunctive thymosin beta 4 treatment holds novel therapeutic potential to regulate and, optimally, resolve disease pathogenesis in the cornea and perhaps other infectious and immune-based inflammatory disease. We plan to establish the importance of thymosin beta 4 as a therapeutic agent in conjunction with antibiotics with high impact for immediate clinical development.

Limitations: No placebo control reported.

2023|International immunopharmacology
PubMed

Interestingly, a balance of neurotrophic factors (nerve growth factor and brain-derived neurotrophic factor) and receptors (nerve growth factor receptor p75, tropomyosin related kinase A and B) were competitively maintained by T&#x3b2;4 through receptors reacting to PrP (106-126). Our results demonstrate that T&#x3b2;4 protects neuronal cells against PrP (106-126) neurotoxicity via the interaction of neurotrophic factors/receptors.

Limitations: No placebo control reported.

2023|Molecules (Basel, Switzerland)
PubMed

We demonstrated that T&#x3b2;4 protein level elevated in all APP/PS1 mice. Over-expression of T&#x3b2;4 alone alleviated AD-like phenotypes of APP/PS1 mice, showed less brain A&#x3b2; accumulation and more Insulin-degrading enzyme (IDE), reversed phenotypic polarization of microglia and astrocyte to a healthy state, improved neuronal function and cognitive behavior performance, and accidentally displayed antidepressant-like effect.

Limitations: Animal study only — human translation uncertain.

2021|Journal of neuroinflammation
PubMed

However, no research has been done to investigate the effects of T&#x3b2;4 on NAFLD. Based on the findings above mentioned, we hypothesize that T&#x3b2;4 may represent an effective treatment for NAFLD.

Limitations: No placebo control reported. Review article — no new primary data.

2020|Chronic diseases and translational medicine
PubMed

These results suggest that T&#x3b2;4 may play a critical role in barrier stabilization. Furthermore, T&#x3b2;4 may prevent neurodegenerative diseases caused by prion-induced BBB dysfunction.

Limitations: No placebo control reported.

2020|European journal of pharmacology
PubMed

It is speculated that F-actinemia contributes to microcirculatory perturbations present in patients with sepsis by disturbing laminar flow. Given that Thymosin Beta 4 inhibits the polymerization of F-actin, it is possible that Thymosin Beta 4 decreases mortality in sepsis via the regulation of actin as well as its other anti-inflammatory properties and should be further pursued as a clinical trial in humans with sepsis.

Limitations: No placebo control reported. Review article — no new primary data.

2019|Expert opinion on biological therapy
PubMed

Expert opinion: The electrifying possibility of T&#x3b2;4 as a revolutionary novel dry eye therapy is something that could have only been dreamed about just a few years ago. We believe that T&#x3b2;4 eyedrops will help many patients suffering from several ocular surface related disorders.

Limitations: No placebo control reported. Review article — no new primary data.

2019|Expert opinion on biological therapy
PubMed

We further highlight three factors that may confound TB4 clinical measurements and should be considered in future study design: 1) residual platelets remaining in suspension after centrifugation, 2) TB4 release following ex vivo platelet activation, and 3) specificity of assays towards posttranslational modifications. Accordingly, we put forth our recommendations to minimize residual and activated platelets during sample collection, and to cross-validate TB4 measurements using both antibody-based and mass spectrometry-based methods.

Limitations: No placebo control reported. Review article — no new primary data.

2019|Expert opinion on biological therapy
PubMed

AREAS COVERED: The authors provide an overview of the T&#x3b2;4's anti-inflammatory properties in several pathologies and provide preliminary evidence on the ability of T&#x3b2;4 to resolve inflammation via the promotion of non-canonical autophagy associated with the activation of the DAP kinase anti-inflammatory function. EXPERT OPINION: Based on its multitasking activity in various animal studies, including tissue repair and prevention of chronic inflammation, T&#x3b2;4 may represent a potential, novel treatment for inflammatory diseases associated with defective autophagy.

Limitations: Preliminary/pilot study — needs larger trials. No placebo control reported. Review article — no new primary data.

2019|Expert opinion on biological therapy
PubMed

Variation in effects and effect sizes in animal models may potentially be due to variable distribution of T&#x3b2;4. Preclinical studies of PK/PD relationships and a reliable pharmacodynamic biomarker would facilitate clinical development of T&#x3b2;4.

Limitations: No placebo control reported. Review article — no new primary data.

2017|Vitamins and hormones
PubMed

T&#x3b2;4 also accelerated the rate of repair in phase 2 trials with patients having pressure ulcers, stasis ulcers, and epidermolysis bullosa wounds. It is safe and well tolerated and will likely have additional uses in the skin and in injured organs for tissue repair and regeneration.

Limitations: No placebo control reported. Review article — no new primary data.

2017|Vitamins and hormones
PubMed

Although the role of T&#x3b2;4 has not been elucidated, it is apparent that T&#x3b2;4 is associated with HSC activation. Therefore, understanding the potential roles and regulatory mechanisms of T&#x3b2;4 in liver fibrosis may provide a novel treatment for patients.

Limitations: No placebo control reported. Review article — no new primary data.

2017|Vitamins and hormones
PubMed

T&#x3b2;4 is expressed endogenously in the activated HSCs, but this endogenous T&#x3b2;4 displays opposite effects in HSC activation, either as an activator or an inhibitor. Although the role of T&#x3b2;4 has not been established, it is apparent that T&#x3b2;4 influences HSC activation, suggesting that T&#x3b2;4 is a potential therapeutic target for treating liver diseases.

Limitations: No placebo control reported. Review article — no new primary data.

2016|International journal of molecular sciences
PubMed

Mechanistically, T&#x3b2;4-overexpressing mice showed increased protein expression levels and phosphorylation of P38, ERK and AKT, whereas knockout mice had decreased levels of both expression and phosphorylation of these proteins. T&#x3b2;4 appears to regulate P38/ERK/AKT signaling via its effect on VEGF expression, with a resultant effect on the speed of hair growth, the pattern of HFs and the number of hair shafts.

Limitations: No placebo control reported.

2016|PloS one
PubMed

Gene expression analysis suggested a thymosin beta 4-dependent regulation of mesenchymal signature genes and modulation of TGF&#x3b2; and p53 signalling networks. We conclude that thymosin beta 4 should be explored as a novel molecular target for anti-glioma therapy.

Limitations: No placebo control reported.

2014|Brain : a journal of neurology
PubMed

Some of these effects are consistent with beta-thymosins functioning exclusively as monomer-binding proteins, while others are not. Therefore, the complex pleiotropic effects of beta-thymosin in cells may be due to direct and indirect effects on the actin cytoskeleton, as well as modulation of signaling pathways that will impact the cytoskeleton and a variety of cell functions.

Limitations: No placebo control reported. Review article — no new primary data.

2007|Annals of the New York Academy of Sciences
PubMed

Treatment of cultured breast cancer cells (SK-BR-3) with 1-4 microg thymosin beta-4/mL significantly increased cell numbers, as determined by MTT-assays. These data reveal an unexpected cellular heterogeneity of thymosin beta-4 expression in breast and colonic carcinomas and suggest that local release of this polypeptide in the tumor microenvironment may modulate tumor behavior.

Limitations: No placebo control reported.

2007|Annals of the New York Academy of Sciences
PubMed

The ability of Tbeta-4 to promote coronary vessel development and potentially induce new vasculature in the adult is essential for cardiomyocyte survival and could contribute significantly toward the reported Tbeta4-induced cardioprotection and repair in the adult heart. Tbeta-4 is currently subject to multicenter phase 1 clinical trials for treatment of cardiovascular disease (http://www.regenerx.com), therefore, insight into the repair mechanism(s) induced by Tbeta-4 is an essential step toward harnessing therapeutic survival, migration, and repair properties of the peptide in the context of acute myocardial damage.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

2007|Annals of the New York Academy of Sciences
PubMed

Community Outcomes

Community Data Coming Soon

Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!

Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.

Important Warnings

  • •Research use only
  • •Limited human safety data
Sourcing, Diagnostic Bloodwork & Telehealth Pathways

Where to get TB-500 (Thymosin Beta-4), baseline labs & clinician oversight.

Full TB-500 (Thymosin Beta-4) $/mg comparison →
50% OFF AUTO-APPLIED$5.40/mg net

Ascension Peptides (US Vials)

MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.

MZ Biolabs COA (Grade A)Claim 50% Off
Verified Vial Suppliers$4.24/mg

SwissChems & Limitless Biotech

Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).

LABS & 503A CLINICS$199/yr Labs · Rx Consult

Superpower Labs & 503A Telehealth

Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.

Code:SPAMBASSADOR

Where to buy TB-500 (Thymosin Beta-4): best verified price

Prices checked Nov 11, 2026 · sorted by $/mg · RUO

  1. 1. SwissChems — $4.24/mg (10mg Lyophilized Vial, $42.36)
  2. 2. Ascension Peptides — $5.40/mg (5mg Lyophilized Vial, $27.00)
  3. 3. Pure Peptides — $6.00/mg (5mg vial, $30.00)

Where is the cheapest place to buy TB-500 (Thymosin Beta-4)?

As of Nov 11, 2026, the lowest verified US domestic single-vial price we found is SwissChems at $4.24/mg (10mg Lyophilized Vial, $42.36). We compared 15 US suppliers with live, checked prices.

How much does TB-500 (Thymosin Beta-4) cost per mg?

Verified US domestic prices currently range from $4.24/mg to $16.50/mg depending on supplier and vial size. Larger vials usually lower the $/mg.

How are these prices verified?

Each price is read from the supplier's own product page or store data and divided by the vial's mg. Suppliers we could not verify are left out rather than estimated. Tables sort strictly by $/mg, never by partner status. Prices are re-checked weekly on our price index.

Is TB-500 (Thymosin Beta-4) approved for human use?

Products from these suppliers are sold for laboratory research use only (RUO). This page is an educational price reference, not medical advice.

All compounds $/mgWeekly $/mg price indexReconstitution calculatorFree cheat sheet

FREE 1-PAGE PDF CHEAT SHEET

Peptide Reconstitution & U-100 Syringe Cheat Sheet

Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.

Unsubscribe anytime.Direct PDF Download

Related Peptides

Popular Stacks

Vendor vs vendor: price per mg

Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.

Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →

Common questions

How many peptides are in the database?

100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.

Where can I compare peptide prices?

Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.